Proteasome inhibitors in the treatment of multiple myeloma.

abstract：:Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently,...

journal_title：Expert review of anticancer therapy

authors： Wong RF,Bhutani MS

更新日期：2005-08-01 00:00:00

abstract：:Metastasis contributes to over 90% of cancer-related deaths. Many types of cancer metastasize via the bloodstream, where circulating tumor cells (CTCs) originating from the primary tumor can undergo selectin-mediated adhesion with the blood vessel wall and subsequently transmigrate to anatomically distant organs. In a...

journal_title：Expert review of anticancer therapy

authors： Mitchell MJ,King MR

更新日期：2014-06-01 00:00:00

abstract：:Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

journal_title：Expert review of anticancer therapy

authors： MacDonald IC,Chambers AF

更新日期：2006-09-01 00:00:00

abstract：:Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

journal_title：Expert review of anticancer therapy

authors： Kim KB,Khuri FR,Shin DM

更新日期：2001-06-01 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：:Background: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, which often leads to dose reduction or drug cessation. We aimed to assess whether hypogonadism is related to treatment with TKIs. ...

journal_title：Expert review of anticancer therapy

authors： Afshar M,Patel HRH,Jain A,Kumar A,Patel P,James ND,Porfiri E

更新日期：2019-06-01 00:00:00

abstract：:Introduction: The microbiota is recognized for its impact on both human health and disease. The human microbiota is made up of trillions of cells, including bacteria, viruses, and fungi. The largest population of microbes reside in the gut, prompting research for better understanding of the impact of gastrointestinal ...

journal_title：Expert review of anticancer therapy

authors： Garajová I,Balsano R,Wang H,Leonardi F,Giovannetti E,Deng D,Peters GJ

更新日期：2020-12-08 00:00:00

abstract：:Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

journal_title：Expert review of anticancer therapy

authors： Tsao CK,Gartrell BA,Oh WK,Galsky MD

更新日期：2012-12-01 00:00:00

abstract：:Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

journal_title：Expert review of anticancer therapy

authors： Smith BD,Smith GL,Buchholz TA

更新日期：2008-03-01 00:00:00

abstract：INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

journal_title：Expert review of anticancer therapy

authors： Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

更新日期：2018-10-01 00:00:00

abstract：:Diffuse brain stem glioma is the most devastating of pediatric malignancies. Virtually all children with this disease die within 1-2 years of diagnosis. After three decades of exhaustive research, the key to controlling this malignancy still eludes us. Attempts to improve survival using radiation, chemotherapy and bio...

journal_title：Expert review of anticancer therapy

authors： Korones DN

更新日期：2007-05-01 00:00:00

abstract：:Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

journal_title：Expert review of anticancer therapy

authors： Mantovani G,Macciò A,Madeddu C,Massa E

更新日期：2003-06-01 00:00:00

abstract：:Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,James ND

更新日期：2002-12-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00

abstract：:Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...

journal_title：Expert review of anticancer therapy

authors： Casadei-Gardini A,Orsi G,Caputo F,Ercolani G

更新日期：2020-01-01 00:00:00

abstract：:Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorab...

journal_title：Expert review of anticancer therapy

authors： Rocco D,Della Gravara L,Battiloro C,Gridelli C

更新日期：2019-07-01 00:00:00

abstract：:Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combin...

journal_title：Expert review of anticancer therapy

authors： Danson SJ,Middleton MR

更新日期：2001-06-01 00:00:00

abstract：:Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

journal_title：Expert review of anticancer therapy

authors： Kortmann RD

更新日期：2014-01-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

journal_title：Expert review of anticancer therapy

authors： Onesti CE,Jerusalem G

更新日期：2020-12-13 00:00:00

abstract：:Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...

journal_title：Expert review of anticancer therapy

authors： Ng VY,Davidson DJ,Kim EY,Pollack SM,Conrad Iii EU,Jones RL

更新日期：2014-07-01 00:00:00

abstract：:Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

journal_title：Expert review of anticancer therapy

authors： Macafee DA,Maxwell-Armstrong C,Scholefield JH

更新日期：2003-08-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

journal_title：Expert review of anticancer therapy

authors： Micali G,Lacarrubba F,Bhatt K,Nasca MR

更新日期：2013-12-01 00:00:00

abstract：:In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

journal_title：Expert review of anticancer therapy

authors： Ciric IS,Zhao J

更新日期：2006-09-01 00:00:00

abstract：:Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

journal_title：Expert review of anticancer therapy

authors： Sathornsumetee S,Rich JN

更新日期：2006-07-01 00:00:00

abstract：:Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

journal_title：Expert review of anticancer therapy

authors： Hussein MR,Baidas S

更新日期：2002-10-01 00:00:00

abstract：:Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

journal_title：Expert review of anticancer therapy

authors： Warsame R,Grothey A

更新日期：2012-10-01 00:00:00

abstract：:The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

journal_title：Expert review of anticancer therapy

authors： Greenberg CC,Bafford AC,Golshan M

更新日期：2008-02-01 00:00:00

abstract：:Ovarian cancer is the leading cause of gynecologic cancer-related death in Europe and the USA. The optimal treatment strategy for this malignancy includes accurate presurgical and surgical staging, optimal debulking surgery, and first-line therapy with platinum-based chemotherapy. Unfortunately, the majority of patien...

journal_title：Expert review of anticancer therapy

authors： Guarneri V,Barbieri E,Dieci MV,Piacentini F,Conte P

更新日期：2011-01-01 00:00:00